Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC)

被引：0
作者：
Gregorc, V.
Novello, S.
Santoro, A.
Grossi, F.
Levra, M. Giaj
Cavina, R.
Vigano, M.
Caligaris-Cappio, F.
Lambiase, A.
Bordignon, C.
机构：
[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[2] Univ Turin, Orbassano, Italy
[3] Ist Clin Humanitas, Rozzano, Italy
[4] Natl Inst Canc Res, Genoa, Italy
[5] Univ Turin, AUO San Luigi, Thorac Oncol Unit, Orbassano, Italy
[6] Ist Clin Humanitas, Dept Oncol, Rozzano, Italy
[7] MolMed SpA, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18043
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomized Phase II Trial of NGR-hTNF and Chemotherapy in Chemo-naive Patients With Non-small Cell Lung Cancer (NSCLC) - Preliminary Results
    Gregorc, V.
    Zilembo, N.
    Grossi, F.
    Rossoni, G.
    Pietrantonio, F.
    Rijavec, E.
    Citterio, G.
    Platania, M.
    Lambiase, A.
    Bordignon, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S596 - S596
  • [32] Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC)
    Furqan, M.
    Zhang, J.
    Clamon, G.
    Abu-Hejleh, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S791 - S791
  • [33] Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
    Santoro, A.
    Pressiani, T.
    Citterio, G.
    Rossoni, G.
    Donadoni, G.
    Pozzi, F.
    Rimassa, L.
    Personeni, N.
    Bozzarelli, S.
    Rossoni, G.
    Colombi, S.
    De Braud, F. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    BRITISH JOURNAL OF CANCER, 2010, 103 (06) : 837 - 844
  • [34] Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
    A Santoro
    T Pressiani
    G Citterio
    G Rossoni
    G Donadoni
    F Pozzi
    L Rimassa
    N Personeni
    S Bozzarelli
    G Rossoni
    S Colombi
    F G De Braud
    F Caligaris-Cappio
    A Lambiase
    C Bordignon
    British Journal of Cancer, 2010, 103 : 837 - 844
  • [35] Phase II study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC).
    Hirose, T.
    Shirai, T.
    Kusumoto, S.
    Sugiyama, T.
    Yamaoka, T.
    Okuda, K.
    Ohmori, T.
    Ohnishi, T.
    Adachi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] RANDOMIZED PHASE II TRIAL OF NGR-HTNF AND CHEMOTHERAPY IN CHEMO-NAIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY RESULTS.
    Gregorc, Vanesa
    Zilembo, N.
    Grossi, Francesco
    Rossoni, Gilda
    Pietrantonio, Filippo
    Rijavec, Erika
    Bulotta, Alessandra
    Vitali, Milena
    Barletta, Giulia
    Bergamaschi, Luca
    Platania, Marco
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S661 - S662
  • [37] PHASE II CLINICAL TRIAL OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), AS SECOND-LINE THERAPY IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Ceresoli, G. L.
    Gregorc, V.
    Zucali, P. A.
    Noberasco, C.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 119 - 119
  • [38] A phase II study of irinotecan (CPT-11) and doxorubicin (DXR) in patients with refractory or relapsed small-cell lung cancer (SCLC).
    Negoro, S
    Uejima, H
    Takeda, K
    Miyazaki, M
    Takihuji, N
    Hirashima, T
    Matsui, K
    Fukuoka, M
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [39] NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study
    Gregorc, V.
    Zucali, P.
    Ceresoli, G. L.
    Noberasco, C.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapy-naive patients with non-small cell lung cancer (NSCLC): Preliminary results.
    Gregorc, V.
    Zilembo, N.
    Grossi, F.
    Rossoni, G.
    Pietrantonio, F.
    Rijavec, E.
    Bulotta, A.
    Vitali, M.
    Barletta, G.
    Bergamaschi, L.
    Platania, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345